Health: research; participation in ibogaine clinical trials; provide for. Amends sec. 7212 of 1978 PA 368 (MCL 333.7212) & adds secs. 2222, 2222a & 2222b.
Key claim: Michigan House Bill 6020 amends the Public Health Code to allow participation in ibogaine clinical trials and adds new sections governing the research framework.
Abstract
(HB6020 · 103rd Legislature) Health: research; participation in ibogaine clinical trials; provide for. Amends sec. 7212 of 1978 PA 368 (MCL 333.7212) & adds secs. 2222, 2222a & 2222b. Latest action (2026-06-09): Recommendation Concurred In
Why this matters
Michigan currently treats ibogaine as a Schedule I controlled substance, foreclosing most therapeutic use; HB 6020 would create a state-sanctioned pathway for clinical trial participation, expanding potential research access for patients — often those with treatment-resistant opioid use disorder — and researchers. The bill sits at the intersection of controlled-substance scheduling, public health research authority, and the state’s broader SUD treatment infrastructure.